XML 28 R19.htm IDEA: XBRL DOCUMENT

Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2022

Percentage of Net Product Sales and Accounts Receivable Balance

The following table includes the percentage of net product sales and accounts receivable balances for our three major Customers, each of which comprised 10% or more of our net product sales:

	Net Product Sales						Accounts Receivable
	Three Months Ended September 30, 2022			Nine Months Ended September 30, 2022			As of September 30, 2022
Customer A		44.8	%		43.9	%		51.6	%
Customer B		36.3	%		36.2	%		34.1	%
Customer C		17.7	%		18.7	%		13.5	%
Total		98.8	%		98.8	%		99.2	%

Summary of Disaggregated Net Product Sales

The following table provides disaggregated net product sales (in thousands):

	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2022		2021		2022		2021
CINVANTI net product sales	$	21,169	$	18,036	$	64,173	$	56,186
SUSTOL net product sales		2,671		3,114		7,179		7,425
ZYNRELEF net product sales		2,717		2,080		6,292		2,080
Total net product sales	$	26,557	$	23,230	$	77,644	$	65,691

Summary of Activity to Product Returns, Distributor Fees and Discounts, Rebates and Administrative Fees

The following table provides a summary of activity with respect to our product returns, distributor fees and discounts, rebates and administrative fees, which are included in other accrued liabilities on the condensed consolidated balance sheets (in thousands):

	Product Returns			Distributor Fees			Discounts, Rebates and Administrative Fees			Total
Balance at December 31, 2021	$	2,579		$	3,466		$	16,515		$	22,560
Provision		1,213			15,301			115,324			131,838
Payments/credits		(699	)		(15,193	)		(110,682	)		(126,574	)
Balance at September 30, 2022	$	3,093		$	3,574		$	21,157		$	27,824

Common Stock Equivalents Excluded From Computation of Net Loss Per Share

Because we have incurred a net loss for all periods presented in the unaudited condensed consolidated statements of operations and comprehensive loss, the following common stock equivalents were not included in the computation of net loss per share because their effect would be anti-dilutive (in thousands):

	September 30,
	2022		2021
Stock options outstanding		20,500		18,257
Restricted stock units outstanding		2,817		641
Warrants outstanding		8,548		25
Shares of common stock underlying convertible notes outstanding		9,819		9,819